Accelerator Life Science Partners Launches Biotechnology Startup Company in Singapore with $16M in Series A Commitments
Accelerator Life Science Partners (ALSP), an early-stage life science accelerator and investment firm that creates and builds next-generation biotechnology companies centered on innovative science, today announced the Series A financing of Automera, a new biotechnology company that focuses on the development of autophagy-targeting chimera small molecules (AUTACs).
- Accelerator Life Science Partners (ALSP), an early-stage life science accelerator and investment firm that creates and builds next-generation biotechnology companies centered on innovative science, today announced the Series A financing of Automera, a new biotechnology company that focuses on the development of autophagy-targeting chimera small molecules (AUTACs).
- The company was established by co-founders Associate Professor Michael Lazarou, Loong Wang, and Taiyang Zhang at Talo Labs Pte Ltd. in collaboration with ALSP.
- Automera has secured $16M in Series A funding, a co-led endeavor by ALSP and ClavystBio, with participation from Singapore-based global investor EDBI, Xora Innovation, and other undisclosed investors.
- “As our first investment in Singapore, Automera exemplifies the innovative scientific and translational research ongoing in the region.